Bio

Clinical Focus


  • Psychiatry

Academic Appointments


  • Clinical Assistant Professor, Psychiatry and Behavioral Sciences

Honors & Awards


  • Young Investigator Award, American Society of Addiction Medicine (2016)
  • Addiction Fellowship, Substance Abuse and Mental Health Services Administration (2015)
  • George Ginsberg MD Fellowship, American Association for Directors of Psychiatric Residency Training (2015)
  • Miller Paper Award, Stanford Psychiatry and Behavioral Sciences (2015)
  • Outstanding Resident Award, Stanford Psychiatry and Behavioral Sciences (2015)
  • Ruth Fox Scholarship, American Society of Addiction Medicine (2015)
  • Leadership Fellowship, Association of Women Psychiatrists (2014)
  • Resident Recognition Award, American Psychiatric Association (2014)
  • Resident Travel Scholarship, American Academy of Addiction Psychiatry, NIDA Sponsored (2014)
  • American Psychiatric Leadership Fellow, American Psychiatric Association (2013)
  • Miller Foundation Research Grant, Stanford Psychiatry (2013)
  • Member, Arnold P. Gold Humanism in Medicine Honor Society (2011)
  • The David Mortimer Olkon Scholarship in Psychiatry and Neurology, University of Illinois (2011)
  • The David and Nancy Morse Scholarship, University of Illinois (2011)
  • The O?Morchoe Award for Excellence in the Promotion of Learning by Medical Students, University of Illinois (2011)
  • First place, Oral Vignette Competition, Research Symposium, University of Illinois (2010)
  • William H. Creswell Award for Outstanding Graduate Student, Community Health University of Illinois (2008)
  • Outstanding Teacher among those rated as Excellent, University of Illinois (2006)
  • Best Scientific Poster, Annual Meeting of the Society of Behavioral Medicine (2003)
  • Silicon Valley Scholars 20,000 award Recipient, Intel/Noyce Foundation (2000)

Boards, Advisory Committees, Professional Organizations


  • Member, Leadership Fellow (former), SAMHSA fellow (Current), American Psychiatric Association (2013 - Present)
  • Member and Leadership Fellow (former), Association of Women Psychiatrists (2014 - Present)
  • Member and former Ruth Fox Fellow, American Society of Addiction Medicine (2015 - Present)
  • Member, American Academy of Addiction Psychiatry (2014 - Present)
  • Scholar, Stanford Society of Physician Scholars (2014 - Present)
  • Councilor, Council on Addictions, American Psychiatric Association (2014 - Present)
  • Secretary, Northern California Psychiatric Society (APA District Branch) (2014 - Present)

Professional Education


  • Board Certification: Addiction Psychiatry, American Board of Psychiatry and Neurology (2016)
  • Fellowship:UCSF Addiction Psychiatry Fellowship (2016) CA
  • Board Certification: Psychiatry, American Board of Psychiatry and Neurology (2015)
  • Residency:Stanford University Adult Psychiatry Residency (2015) CA
  • Medical Education:University of Illinois at Chicago College of Medicine Urbana (2011) IL
  • Board Certified, American Board of Psychiatry and Neurology, Addiction Psychiatry (2016)
  • Board Certified, American Board of Psychiatry & Neurology, Psychiatry (2015)
  • Addiction Psychiatry Fellowship, UCSF (2016)
  • Psychiatry Residency, Stanford Psychiatry and Behavioral Sciences (2015)
  • MD, University of Illinois at Urbana Champaign (2011)
  • PhD, University of Illinois at Urbana Champaign, Community Health (2010)
  • MPH, Dartmouth College, Public Health (2005)
  • BS, Stanford University, Chemistry, Statistics (2004)

Publications

All Publications


  • Treating Smoking in Adults With Co-occurring Acute Psychiatric and Addictive Disorders. Journal of addiction medicine Das, S., Hickman, N. J., Prochaska, J. J. 2017

    Abstract

    Tobacco use is undertreated in individuals with psychiatric and substance use disorders (SUDs), with concerns that quitting smoking may compromise recovery. We evaluated outcomes of a tobacco intervention among psychiatric patients with co-occurring SUDs.Data from 2 randomized tobacco treatment trials conducted in inpatient psychiatry were combined; analyses focused on the subsample with co-occurring SUDs (n?=?216). Usual care provided brief advice to quit and nicotine replacement therapy during the smoke-free hospitalization. The intervention, initiated during hospitalization and continued 6 months after hospitalization, was tailored to readiness to quit smoking, and added a computer-assisted intervention at baseline, and 3 and 6 months; brief counseling; and 10 weeks of nicotine replacement therapy after hospitalization. Outcomes were 7-day point prevalence abstinence from 3 to 12 months and past 30-day reports of alcohol and illicit drug use.The sample consisted of 34% women, among which 36% were Caucasian, averaging 19?cigarettes/d prehospitalization; the groups were comparable at baseline. At 12 months, 22% of the intervention versus 11% of usual care participants were tobacco-abstinent (risk ratio 2.01, P?=?0.03). Past 30-day abstinence from alcohol/drugs did not differ by group (22%); however, successful quitters were less likely than continued smokers to report past 30-day cannabis (18% vs 42%) and alcohol (22% vs 58%) use (P?

    View details for DOI 10.1097/ADM.0000000000000320

    View details for PubMedID 28441272

  • Smoking, Mental Illness, and Public Health. Annual review of public health Prochaska, J. J., Das, S., Young-Wolff, K. C. 2016

    Abstract

    Tobacco remains the leading preventable cause of death worldwide. In particular, people with mental illness are disproportionately affected with high smoking prevalence; they account for more than 200,000 of the 520,000 tobacco-attributable deaths in the United States annually and die on average 25 years prematurely. Our review aims to provide an update on smoking in the mentally ill. We review the determinants of tobacco use among smokers with mental illness, presented with regard to the public health HAVE framework of "the host" (e.g., tobacco user characteristics), the "agent" (e.g., nicotine product characteristics), the "vector" (e.g., tobacco industry), and the "environment" (e.g., smoking policies). Furthermore, we identify the significant health harms incurred and opportunities for prevention and intervention within a health care systems and larger health policy perspective. A comprehensive effort is warranted to achieve equity toward the 2025 Healthy People goal of reducing US adult tobacco use to 12%, with attention to all subgroups, including smokers with mental illness. Expected final online publication date for the Annual Review of Public Health Volume 38 is March 20, 2017. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

    View details for DOI 10.1146/annurev-publhealth-031816-044618

    View details for PubMedID 27992725

  • Smoking Trends Among Adults With Behavioral Health Conditions in Integrated Health Care: A Retrospective Cohort Study. Psychiatric services Young-Wolff, K. C., Kline-Simon, A. H., Das, S., Mordecai, D. J., Miller-Rosales, C., Weisner, C. 2016; 67 (9): 996-1003

    Abstract

    Individuals with behavioral health conditions (BHCs) smoke at high rates and have limited success with quitting, despite impressive gains in recent decades in reducing the overall prevalence of smoking in the United States. This study examined smoking disparities among individuals with BHCs within an integrated health care delivery system with convenient access to tobacco treatments.The sample consisted of patients in an integrated health care delivery system in 2010-a group (N=155,733) with one or more of the five most prevalent BHCs (depressive disorders, anxiety disorders, substance use disorders, bipolar and related disorders, and attention-deficit hyperactivity disorder) and a group (N=155,733) without BHCs who were matched on age, sex, and medical home facility. The odds of smoking among patients with BHCs versus without BHCs were examined over four years using logistic regression generalized estimating equation models. Tobacco cessation medication utilization among a subset of smokers in 2010 was also examined.Although smoking prevalence decreased from 2010 to 2013 overall, the likelihood of smoking decreased significantly more slowly among patients with BHCs compared with patients without BHCs (p<.001), most notably among patients with substance use and bipolar and related disorders. Tobacco cessation medication use was low, and smokers with BHCs were more likely than smokers without BHCs to utilize these products (6.2% versus 3.6%, p<.001).Smoking decreased more slowly among individuals with BHCs compared with individuals without BHCs, even within an integrated health care system, highlighting the need to prioritize smoking cessation within specialty behavioral health treatment.

    View details for DOI 10.1176/appi.ps.201500337

    View details for PubMedID 27079992

  • Update on Smoking Cessation: E-Cigarettes, Emerging Tobacco Products Trends, and New Technology-Based Interventions. Current psychiatry reports Das, S., Tonelli, M., Ziedonis, D. 2016; 18 (5): 51

    Abstract

    Tobacco use disorders (TUDs) continue to be overly represented in patients treated in mental health and addiction treatment settings. It is the most common substance use disorder (SUD) and the leading cause of health disparities and increased morbidity/mortality amongst individuals with a psychiatric disorder. There are seven Food and Drug Administration (FDA) approved medications and excellent evidence-based psychosocial treatment interventions to use in TUD treatment. In the past few years, access to and use of other tobacco or nicotine emerging products are on the rise, including the highly publicized electronic cigarette (e-cigarette). There has also been a proliferation of technology-based interventions to support standard TUD treatment, including mobile apps and web-based interventions. These tools are easily accessed 24/7 to support outpatient treatment. This update will review the emerging products and counter-measure intervention technologies, including how clinicians can integrate these tools and other community-based resources into their practice.

    View details for DOI 10.1007/s11920-016-0681-6

    View details for PubMedID 27040275

  • Intravenous Use of Intranasal Naloxone: A Case of Overdose Reversal. Substance abuse Das, S., Shah, N., Ghadiali, M. 2016: 0

    Abstract

    Opioid overdose is a growing concern in the United States and internationally. Prehospital or pre-medical-personnel (lay person) administration of naloxone, an opioid antagonist, to reverse overdose, is an expanding mode of harm reduction. Recently, community clinics, methadone clinics, needle exchanges, some pharmacies and other health care facilities have made naloxone available to the community.This case describes heroin overdose reversal of a 28-year-old male who had been using about a gram of heroin intravenously for 3 years, but recently reduced frequency of use in an attempt to stop. He was seen initially 1 week prior to a buprenorphine induction in our clinic. After the initial intake he used intravenous heroin, a larger amount than over the past several weeks in anticipation of abstinence, lost consciousness and was difficult to arouse. A friend with him noted the patient's respirations to become shallow and administered naloxone nasal spray that the patient had obtained from a needle exchange, but did so intravenously by attaching an unused drug needle to the syringe barrel in place of the nasal atomizer. The patient's overdose was reversed and he recovered.This is the first known published case of a community-distributed naloxone nasal spray being used intravenously by a lay person (bystander). The case emphasizes the efficacy of naloxone in overdose reversal, and also the need for education or instructions on naloxone use by others (not just the user). Finally it highlights the risk of overdose in those entering treatment, seeking intoxication one last time.

    View details for PubMedID 27925864

  • Addiction Training: Striving to Fill an Unmet Need. Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry Das, S., Roberts, L. W. 2016

    View details for PubMedID 27020933

  • Prospective Validation Study of the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) in Medically Ill Inpatients: A New Scale for the Prediction of Complicated Alcohol Withdrawal Syndrome ALCOHOL AND ALCOHOLISM Maldonado, J. R., Sher, Y., Das, S., Hills-Evans, K., Frenklach, A., Lolak, S., Talley, R., Neri, E. 2015; 50 (5): 509-518

    Abstract

    The prevalence of alcohol use disorders (AUDs) among hospitalized medically ill patients exceeds 40%. Most AUD patients experience uncomplicated alcohol withdrawal syndrome (AWS), requiring only supportive medical intervention, while complicated AWS occurs in up to 20% of cases (i.e. seizures, delirium tremens). We aimed to prospectively test and validate the Prediction of Alcohol Withdrawal Severity Scale (PAWSS), a new tool to identify patients at risk for developing complicated AWS, in medically ill hospitalized patients.We prospectively considered all subjects hospitalized to selected general medicine and surgery units over a 12-month period. Participants were assessed independently and blindly on a daily basis with PAWSS, Clinical Institute Withdrawal Assessment-Alcohol, Revised (CIWA-Ar) and clinical monitoring throughout their admission to determine the presence and severity of AWS.Four hundred and three patients were enrolled in the study. Patients were grouped by PAWSS score: Group A (PAWSS < 4; considered at low risk for complicated AWS); Group B (PAWSS ? 4; considered at high risk for complicated AWS). The results of this study suggest that, using a PAWSS cutoff of 4, the tool's sensitivity for identifying complicated AWS is 93.1% (95%CI[77.2, 99.2%]), specificity is 99.5% (95%CI[98.1, 99.9%]), positive predictive value is 93.1% and negative predictive value is 99.5%; and has excellent inter-rater reliability with Lin's concordance coefficient of 0.963 (95% CI [0.936, 0.979]).PAWSS has excellent psychometric characteristics and predictive value among medically ill hospitalized patients, helping clinicians identify those at risk for complicated AWS and allowing for prevention and timely treatment of complicated AWS.

    View details for DOI 10.1093/alcalc/agv043

    View details for Web of Science ID 000363934400004

    View details for PubMedID 25999438

  • Chapter 144: Tobacco, Smoking and Mental Health Encyclopedia of Mental Health Das, S., Prochaska, J. J. Elsevier . 2015; 2
  • Smoking & Mental Illness: Strategies to Increase Screening, Assessment & Treatment The Journal of Lifelong Learning in Psychiatry Zidonis, D., Das, S., Tonelli, M. 2015; 12 (3): 290-306
  • Bus therapy: a problematic practice in psychiatry. JAMA psychiatry Das, S., Fromont, S. C., Prochaska, J. J. 2013; 70 (11): 1127-1128

    View details for DOI 10.1001/jamapsychiatry.2013.2824

    View details for PubMedID 24068366

  • Cytisine, the world's oldest smoking cessation aid. BMJ (Clinical research ed.) Prochaska, J. J., Das, S., Benowitz, N. L. 2013; 347: f5198-?

    View details for DOI 10.1136/bmj.f5198

    View details for PubMedID 23974638

  • Infection and the Risk of Topical Anesthetic Induced Clinically Significant Methemoglobinemia after Transesophageal Echocardiography ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES Vallurupalli, S., Das, S., Manchanda, S. 2010; 27 (3): 318-323

    Abstract

    Methemoglobinemia is a recognized complication of topical anesthesia with benzocaine during transesophageal echocardiography (TEE). Though several risk factors have been described, the importance of individual factors is not known. We performed a retrospective study to identify determinants of the risk of methemoglobinemia.All patients who underwent TEE with benzocaine topical anesthesia between June 2005 and June 2007 were included in this retrospective study.Of the 886 patients who were included in the study, 140 had active infection (15.8%). The incidence of methemoglobinemia in this group was 2.9% (vs. 0%, P < 0.001). Compared to those without infection, patients in the active infection group were more likely to have a lower hemoglobin (P < 0.001), serum albumin level (P < 0.001), glomerular filtration rate less than 60 ml/min per 1.73 m(2) (P < 0.001), higher rates of dialysis (P < 0.001), a higher incidence of malignancy (P = 0.01), and increased use of acetaminophen and sulfa drugs (P < 0.001). However, multivariate logistic regression analysis did not identify any statistically significant covariates.In conclusion, patients with an active systemic infection who undergo TEE are at a higher risk of methemoglobinemia. However, none of the risk factors for methemoglobinemia including active infection reached statistical significance in the regression analysis which has to be interpreted with caution in view of the low event rate.

    View details for DOI 10.1111/j.1540-8175.2009.00994.x

    View details for Web of Science ID 000275757300017

    View details for PubMedID 19725841

  • Clinical efficacy of beta1 selective adrenergic blockers in the treatment of neurocardiogenic syncope - a meta-analysis. Clinical pharmacology : advances and applications Vallurupalli, S., Das, S. 2010; 2: 163-167

    Abstract

    Beta1 (B(1)) selective blockers have been widely used for the treatment of neurocardiogenic syncope though clinical trials have shown conflicting degrees of efficacy.To study the clinical efficacy of B(1) selective blockers compared to placebo in the treatment of neurocardiogenic syncope.Four placebo controlled randomized studies were identified after search of existing English language literature. Review Manager (RevMan version 5, Oxford, England) was used for statistical calculations. Both random and fixed effects models were used for analysis.There was no demonstrable efficacy of B(1) blockers compared to placebo even after a pre-specified sensitivity analysis. There was a trend towards more adverse events in the beta blocker group compared to placebo (OR = 2.03 CI = 0.83-3.95, p = 0.12).There is no clinical evidence for justifying the use of B(1) selective blockers in the treatment of adult neurocardiogenic syncope. These agents may in fact lead to a higher rate of adverse events compared to placebo.

    View details for DOI 10.2147/CPAA.S12873

    View details for PubMedID 22291501

  • Reliability of self-report: paper versus online administration COMPUTERS IN HUMAN BEHAVIOR Luce, K. H., Winzelberg, A. J., Das, S., Osborne, M. I., Bryson, S. W., Taylor, C. B. 2007; 23 (3): 1384-1389
  • Who pays for poor surgical quality? Building a business case for quality improvement JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS Dimick, J. B., Weeks, W. B., Karia, R. J., Das, S., Campbell, D. A. 2006; 202 (6): 933-937

    Abstract

    Both providers and payors bear the financial risk associated with complications of poor quality care. But the stakeholder who bears the largest burden of this risk has a strong incentive to support quality improvement activities. The goal of the present study was to determine whether hospitals or payors incur a larger burden of increased hospital costs associated with complications.We merged clinical data for 1,008 surgical patients from the private sector National Surgical Quality Improvement Program to the internal cost-accounting database of a large university hospital. We then determined the marginal costs of surgical complications from the perspective of both hospitals (changes in profit and profit margin) and payors (increase in reimbursement paid to the hospital). In our analyses of cost and reimbursement, we adjusted for procedure complexity and patient characteristics using multivariate linear regression.Reimbursement for patients without complications ($14,266) exceeded hospital costs ($10,978), generating an average hospital profit of $3,288 and a profit margin of 23%. When complications occurred, hospitals still received reimbursement in excess of their costs, but the profit margin declined: reimbursement ($21,911) exceeded hospital costs ($21,156), yielding an average profit of $755 and a profit margin of 3.4%. Complications were always associated with an increase in costs to health-care payors: complications were associated with an average increase in reimbursement of $7,645 (54%) per patient.Hospitals and payors both suffer financial consequences from poor-quality health care, but the greater burden falls on health-care payors. Strong incentives exist for health-care payors to become more involved in supporting quality improvement activities.

    View details for DOI 10.1016/j.jamcollsurg.2006.02.015

    View details for Web of Science ID 000238071300011

    View details for PubMedID 16735208

  • Application of an algorithm-driven protocol to simultaneously provide universal and targeted prevention programs INTERNATIONAL JOURNAL OF EATING DISORDERS Luce, K. H., Osborne, M. I., Winzelberg, A. J., Das, S., Abascal, L. B., Celio, A. A., Wilfley, D. E., Stevenson, D., Dev, P., Taylor, C. B. 2005; 37 (3): 220-226

    Abstract

    Our objective was to develop a model to simultaneously prevent eating disorders and weight gain among female high school students.Of 188 female 10th graders enrolled in health classes, 174 elected to participate in the current study. They were assessed on-line and decided to participate in one of four interventions appropriate to their risk.The algorithm identified 111 no-risk (NR), 36 eating disorder risk (EDR), 16 overweight risk (OR), and 5 both risks. Fifty-six percent of the EDR and 50% of the OR groups elected to receive the recommended targeted curricula. Significant improvements in weight and shape concerns were observed in all groups.An Internet-delivered program can be used to assess risk and provide simultaneous universal and targeted interventions in classroom settings.

    View details for DOI 10.1002/eat.20089

    View details for Web of Science ID 000228875900005

    View details for PubMedID 15822091

  • Dissemination of an effective inpatient tobacco use cessation program NICOTINE & TOBACCO RESEARCH Taylor, C. B., Miller, N. H., Cameron, R. P., Fagans, E. W., Das, S. 2005; 7 (1): 129-137

    Abstract

    The present study aimed to determine whether tobacco use cessation rates observed in controlled trials of a hospital-based tobacco use cessation program could be replicated when the program was disseminated to a wide range of hospitals in a two-stage process including implementation and institutionalization phases. Using a nonrandomized, observational design, we recruited six hospitals to participate in the study. The research team helped implement the program during the first year of participation (implementation) and then withdrew from active involvement during the second year (institutionalization). The mean 6-month self-reported cessation rates were 26.3% (range = 17.6%-52.8%) for the implementation phase and 22.7% (range = 12.9%-48.2%) for the institutionalization phase. Hospitals with paid professionals providing the program had the best outcomes. Inpatient tobacco use cessation programs are feasible to implement and should target a 6-month self-reported cessation rate of at least 25%.

    View details for DOI 10.1080/14622200412331328420

    View details for Web of Science ID 000228642300013

    View details for PubMedID 15804685

  • Reliability of Self-Report: Paper versus Online Administration Computers in Human Behavior Luce, K. H., Winzelberg, A. J., Das, S., Osborne, M., Bryson, S. W., Taylor, C. B. 2003; 23 (3): 1384-1389

Footer Links:

Stanford Medicine Resources: